Form 4: Rani Therapeutics Holdings CEO Reports Stock Transaction
Insider Transaction (Form 4)
Talat Imran, Chief Executive Officer and a Director of Rani Therapeutics Holdings, Inc., reported a transaction in 7,928 shares of common stock on September 27, 2026.
Summary
- Tax/exercise-price withholding: disposed of 7,928 Class A Common Stock at $0.76 ($6,019) on September 27, 2026; holds 461,808 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Talat Imran — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-27 | Tax/exercise-price withholding | Class A Common Stock | 7,928 | $1 | $6.0K | 461,808 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-27 | Tax/exercise-price withholding (7,928 shares) |
Keywords
insider transaction, Form 4, RANI, Rani Therapeutics Holdings, Inc., neutral, Talat Imran
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.